索拉非尼治疗肝细胞肝癌不良反应的护理  

Nursing of sorafenib for the treatment of adverse reactions of hepatocellular carcinoma

作　　者：陆美芹[1] 蔡守平[1] 沈茜[1] 

机构地区：[1]江苏省南通市肿瘤医院肝胆科,江苏南通226361

出　　处：《实用临床医药杂志》2013年第4期4-5,9,共3页Journal of Clinical Medicine in Practice

摘　　要：目的探讨索拉非尼治疗中晚期肝细胞肝癌的不良反应及护理措施。方法回顾性分析26例中晚期肝细胞肝癌患者服用索拉非尼期间出现的不良反应。结果 26例患者发生的不良反应有手足综合征(57.7%)、腹泻(53.8%)、高血压(50.0%)、皮疹(46.2%)、疲乏(46.2%)等,一般为1～2级,仅1例患者出现3级手足综合征,予减半量治疗,所有患者经护理干预后不良反应均有所好转。结论索拉非尼作为分子靶向治疗新药,服药期间应严密观察患者的不良反应,及时采取有效的护理干预,从而提高治疗疗效和患者的生活质量。Objective To explore the adverse reactions and nursing measures for advanced hepatocellular carcinoma treated with sorafenib.Methods Adverse reactions of 26 advanced hepatocellular carcinoma patients treated with sorafenib were analyzed retrospectively.Results The main adverse reactions occurred in 26 patients were hand-foot syndrome（57.7%）,diarrhea（53.8%）,hypertension（50.0%）,skin rash（46.2%）,fatigue（46.2%）,etc.Most of adverse reactions were grade 1～2.Only one patient had grade 3 hand-foot syndrome and was treated with 50% dosage of sorafenib.Adverse reactions in all the patients were improved by the nursing intervention.Conclusion Being a new drug for molecular targeted therapy,the adverse reactions in application of sorafenib should be strictly observed,and the effective nursing interventional should be implemented timely in order to improve the therapeutic effect and quality of life of patients.

关 键 词：索拉非尼 中晚期肝细胞肝癌 不良反应 护理 

分 类 号：R473.73[医药卫生—护理学]